Qube Research & Technologies (QRT)
VKTX icon

Qube Research & Technologies (QRT)’s Viking Therapeutics VKTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,000
Closed -$1.39M – 4782
2024
Q1 		$1.39M Buy
+17,000
New +$756K ﹤0.01% 1950

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VKTX Position: Q2 2024 in Review

Qube Research & Technologies (QRT) sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 27,688 shares — an estimated $2.27M sold.

Qube Research & Technologies (QRT) first reported a position in VKTX in Q2 2020 and held it in 9 quarters. The position peaked at $2.27M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Qube Research & Technologies (QRT) reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 27,688 Viking Therapeutics shares in Q2 2024, an estimated $2.27M.
  • Qube Research & Technologies (QRT) first reported a position in Viking Therapeutics in Q2 2020 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Viking Therapeutics position peaked at $2.27M in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2024, filed 14 Aug 2024.